{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:33:19Z","timestamp":1787956399535,"version":"build-2784847793"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T00:00:00Z","timestamp":1429142400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s10198-015-0685-x","type":"journal-article","created":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T12:52:58Z","timestamp":1429102378000},"page":"391-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs"],"prefix":"10.1007","volume":"17","author":[{"given":"Marieke","family":"Krol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joc\u00e9","family":"Papenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siok Swan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Hakkaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,16]]},"reference":[{"key":"685_CR1","unstructured":"ISPOR: pharmacoeconomic guidelines around the world. http:\/\/www.ispor.org\/PEguidelines\/index.asp . Accessed 18 Aug 2011"},{"key":"685_CR2","unstructured":"National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal (2008)"},{"key":"685_CR3","doi-asserted-by":"crossref","unstructured":"Johannesson M., J\u00f6nsson, B., J\u00f6nsson, L., Kobelt, G., Zethraeus, N.: Why should economic evaluations of medical innovations have a societal perspective? OHE briefing (2009)","DOI":"10.2139\/ssrn.2640123"},{"key":"685_CR4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"B Jonsson","year":"2009","unstructured":"Jonsson, B.: Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 10, 357\u2013359 (2009)","journal-title":"Eur J Health Econ"},{"key":"685_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0168-8510(94)00677-7","volume":"33","author":"MA Johannesson","year":"1995","unstructured":"Johannesson, M.A.: Note on the depreciation of the societal perspective in economic evaluation of health care. Health Policy 33, 59\u201366 (1995)","journal-title":"Health Policy"},{"key":"685_CR6","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"M Gold","year":"1996","unstructured":"Gold, M., Siegel, J., Russell, L., Weinstein, M.: Cost-effectiveness in health and medicine. Oxford University Press, Oxford (1996)"},{"key":"685_CR7","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2005","unstructured":"Drummond, M.F., Sculpher, M.J., Torrance, G.W., O\u2019Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford (2005)"},{"key":"685_CR8","unstructured":"Claxton, K., Walker, S., Palmer, S., Sculpher, M.: Appropriate perspectives for health care decisions. CHE Reasearch paper 54 (2010)"},{"key":"685_CR9","unstructured":"The government\u2019s response to the Health Select Committee\u2019s eighth report of session 2012\u201313 on the National Institute for Health and Clinical Excellence (2013)"},{"key":"685_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/(SICI)1099-1050(199709)6:5<511::AID-HEC297>3.0.CO;2-K","volume":"6","author":"WB Brouwer","year":"1997","unstructured":"Brouwer, W.B., Koopmanschap, M.A., Rutten, F.F.: Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 6, 511\u2013514 (1997)","journal-title":"Health Econ."},{"key":"685_CR11","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2165\/11539970-000000000-00000","volume":"29","author":"M Krol","year":"2011","unstructured":"Krol, M., Papenburg, J., Koopmanschap, M., Brouwer, W.: Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 29, 601\u2013619 (2011)","journal-title":"Pharmacoeconomics"},{"key":"685_CR12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1017\/S0266462300161100","volume":"16","author":"PW Stone","year":"2000","unstructured":"Stone, P.W., Chapman, R.H., Sandberg, E.A., Liljas, B., Neumann, P.J.: Measuring costs in cost-utility analyses. Variations in the literature. Int. J. Technol. Assess. Health Care 16, 111\u2013124 (2000)","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"685_CR13","volume-title":"Productivity costs: principles and practice in economic evaluation","author":"C Pritchard","year":"2000","unstructured":"Pritchard, C., Sculpher, M.: Productivity costs: principles and practice in economic evaluation. Office of Health Economics, London (2000)"},{"key":"685_CR14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1524-4733.2006.00123.x","volume":"9","author":"WBF Brouwer","year":"2006","unstructured":"Brouwer, W.B.F., Exel, J.A., Baltussen, R.M.P.M., Rutten, F.F.H.: A dollar is a dollar\u2014or is it? Value Health 9, 341\u2013347 (2006)","journal-title":"Value Health"},{"key":"685_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0149-2918(00)88283-1","volume":"21","author":"EA Rothermich","year":"1999","unstructured":"Rothermich, E.A., Pathak, D.S.: Productivity-cost controversies in cost-effectiveness analysis: review and research agenda. Clin. Ther. 21, 255\u2013267 (1999)","journal-title":"Clin. Ther."},{"key":"685_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0168-8510(92)90022-4","volume":"21","author":"K Gerard","year":"1992","unstructured":"Gerard, K.: Cost-utility in practice: a policy maker\u2019s guide to the state of the art. Health Policy 21, 249\u2013279 (1992)","journal-title":"Health Policy"},{"key":"685_CR17","first-page":"179","volume":"52","author":"C Hoffmann","year":"2000","unstructured":"Hoffmann, C., Graf von der Schulenburg, J.: The influence of economic evaluation studies on decision making. A European survey. EUROMET Group 52, 179\u2013192 (2000)","journal-title":"EUROMET Group"},{"key":"685_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40273-014-0209-z","volume":"33","author":"K Tang","year":"2014","unstructured":"Tang, K.: Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence. Pharmacoeconomics 33, 31\u201348 (2014)","journal-title":"Pharmacoeconomics"},{"key":"685_CR19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.socscimed.2010.10.026","volume":"72","author":"W Zhang","year":"2011","unstructured":"Zhang, W., Bansback, N., Anis, A.H.: Measuring and valuing productivity loss due to poor health: a critical review. Soc. Sci. Med. 72, 185\u2013192 (2011)","journal-title":"Soc. Sci. Med."},{"key":"685_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40273-014-0132-3","volume":"32","author":"M Krol","year":"2014","unstructured":"Krol, M., Brouwer, W.: How to estimate productivity costs in economic evaluations. Pharmacoeconomics 32, 335\u2013344 (2014)","journal-title":"Pharmacoeconomics"},{"key":"685_CR21","doi-asserted-by":"crossref","unstructured":"Krol, M., Brouwer, W., Rutten, F.: Productivity costs in economic evaluations: past, present, future. Pharmacoeconomics, (2013)","DOI":"10.1007\/s40273-013-0056-3"},{"key":"685_CR22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/258535","volume":"69","author":"BA Weisbrod","year":"1961","unstructured":"Weisbrod, B.A.: The valuation of human capital. J. Polit. Econ. 69, 425\u2013436 (1961)","journal-title":"J. Polit. Econ."},{"key":"685_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","volume":"14","author":"MA Koopmanschap","year":"1995","unstructured":"Koopmanschap, M.A., Rutten, F.F., van Ineveld, B.M., van Roijen, L.: The friction cost method for measuring indirect costs of disease. J Health Econ 14, 171\u2013189 (1995)","journal-title":"J Health Econ"},{"key":"685_CR24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hec.4730030606","volume":"3","author":"MA Koopmanschap","year":"1994","unstructured":"Koopmanschap, M.A., Rutten, F.F.: The impact of indirect costs on outcomes of health care programs. Health Econ. 3, 385\u2013393 (1994)","journal-title":"Health Econ."},{"key":"685_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1478-7547-6-6","volume":"6","author":"L Lindholm","year":"2008","unstructured":"Lindholm, L., Lofroth, E., Rosen, M.: Does productivity influence priority setting? A case study from the field of CVD prevention. Cost Eff Resour Alloc 6, 6 (2008)","journal-title":"Cost Eff Resour Alloc"},{"key":"685_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0277-9536(99)00116-1","volume":"49","author":"J Olsen","year":"1999","unstructured":"Olsen, J., Richardson, J.: Production gains from health care: what should be included in cost-effectiveness analysis. Soc. Sci. Med. 49, 17\u201326 (1999)","journal-title":"Soc. Sci. Med."},{"key":"685_CR27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jme.18.1.7","volume":"18","author":"A Williams","year":"1992","unstructured":"Williams, A.: Cost-effectiveness analysis: is it ethical? J. Med. Ethics 18, 7\u201311 (1992)","journal-title":"J. Med. Ethics"},{"key":"685_CR28","unstructured":"Australian Government Department of Health and Ageing: Pharmaceutical Benefits Advisory Committee: Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. December (2008)"},{"key":"685_CR29","unstructured":"Grocott, R., Metcalfe, S., Schoeler, R., Priest, V., Hall, C., Brougham, M., Poynton, M.: Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. PHARMAC Pharmaceutical Management Agency (2007)"},{"key":"685_CR30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2146\/ajhp120759","volume":"70","author":"JM Hoffman","year":"2013","unstructured":"Hoffman, J.M., Li, E., Doloresco, F., Matusiak, L., Hunkler, R.J., Shah, N.D., Vermeulen, L.C., Schumock, G.T.: Projecting future drug expenditures in US nonfederal hospitals and clinics\u20132013. Am. J. Health Syst. Pharm. 70, 525\u2013539 (2013)","journal-title":"Am. J. Health Syst. Pharm."},{"key":"685_CR31","unstructured":"Nederlandse zorgautoriteit: http:\/\/www.nza.nl\/137706\/145406\/CI-1135.pdf (2009). Accessed 22 June 2013"},{"key":"685_CR32","unstructured":"Eurostat: annual average rate of change in harmonized indices of consumer prices (HICPs). http:\/\/epp.eurostat.ec.europa.eu\/tgm\/table.do?tab=table&init=1&plugin=1&language=en&pcode=tsieb060 . Accessed 03 July 2011"},{"key":"685_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.24169","volume":"61","author":"WB Hout van den","year":"2009","unstructured":"van den Hout, W.B., Goekoop-Ruiterman, Y.P., Allaart, C.F., de Vries-Bouwstra, J.K., Hazes, J.M., Kerstens, P.J., van Zeben, D., Hulsmans, H.M., de Jonge-Bok, J.M., de Sonnaville, P.B., Dijkmans, B.A., Breedveld, F.C.: Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 61, 291\u2013299 (2009)","journal-title":"Arthritis Rheum."},{"key":"685_CR34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/02841860500247503","volume":"44","author":"J Norum","year":"2005","unstructured":"Norum, J., Holtmon, M.: Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Acta Oncol. 44, 735\u2013741 (2005)","journal-title":"Acta Oncol."},{"key":"685_CR35","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/kem074","volume":"46","author":"CA Walsh","year":"2007","unstructured":"Walsh, C.A., Minnock, P., Slattery, C., Kennedy, N., Pang, F., Veale, D.J., Bresnihan, B., FitzGerald, O.: Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 46, 1148\u20131152 (2007)","journal-title":"Rheumatology (Oxford)"},{"key":"685_CR36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1185\/03007990902719117","volume":"25","author":"N Maniadakis","year":"2009","unstructured":"Maniadakis, N., Fragoulakis, V., Pectasides, D., Fountzilas, G.: XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr. Med. Res. Opin. 25, 797\u2013805 (2009)","journal-title":"Curr. Med. Res. Opin."},{"key":"685_CR37","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1017\/S0266462307070432","volume":"23","author":"G Kobelt","year":"2007","unstructured":"Kobelt, G., Sobocki, P., Sieper, J., Braun, J.: Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care 23, 368\u2013375 (2007)","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"685_CR38","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/rheumatology\/keh271","volume":"43","author":"G Kobelt","year":"2004","unstructured":"Kobelt, G., Andlin-Sobocki, P., Brophy, S., J\u00f6nsson, L., Calin, A., Braun, J.: The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 43, 1158\u20131166 (2004)","journal-title":"Rheumatology (Oxford)"},{"key":"685_CR39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","volume":"26","author":"R Gani","year":"2008","unstructured":"Gani, R., Giovannoni, G., Bates, D., Kemball, B., Hughes, S., Kerrigan, J.: Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 26, 617\u2013627 (2008)","journal-title":"Pharmacoeconomics"},{"key":"685_CR40","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ygyno.2007.05.043","volume":"106","author":"RE Bristow","year":"2007","unstructured":"Bristow, R.E., Santillan, A., Salani, R., Diaz-Montes, T.P., Giuntoli, R.L., Meisner, B.C., Armstrong, D.K., Frick, K.D.: Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol. Oncol. 106, 476\u2013481 (2007)","journal-title":"Gynecol. Oncol."},{"key":"685_CR41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3899\/jrheum.080257","volume":"36","author":"A Davies","year":"2009","unstructured":"Davies, A., Cifaldi, M.A., Segurado, O.G., Weisman, M.H.: Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J. Rheumatol. 36, 16\u201326 (2009)","journal-title":"J. Rheumatol."},{"key":"685_CR42","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2165\/00019053-200624120-00006","volume":"24","author":"JR Spalding","year":"2006","unstructured":"Spalding, J.R., Hay, J.: Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 24, 1221\u20131232 (2006)","journal-title":"Pharmacoeconomics"},{"key":"685_CR43","first-page":"732","volume":"33","author":"G Kobelt","year":"2006","unstructured":"Kobelt, G., Andlin-Sobocki, P., Maksymowych, W.P.: The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J. Rheumatol. 33, 732\u2013740 (2006)","journal-title":"J. Rheumatol."},{"key":"685_CR44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0002-9343(02)01243-3","volume":"113","author":"JB Wong","year":"2002","unstructured":"Wong, J.B., Singh, G., Kavanaugh, A.: Estimating the cost-effectiveness of 54\u00a0weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400\u2013408 (2002)","journal-title":"Am. J. Med."},{"key":"685_CR45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMsa020969","volume":"347","author":"BJ Manns","year":"2002","unstructured":"Manns, B.J., Lee, H., Doig, C.J., Johnson, D., Donaldson, C.: An economic evaluation of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 993\u20131000 (2002)","journal-title":"N. Engl. J. Med."},{"key":"685_CR46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S0266462309090230","volume":"25","author":"P Lindgren","year":"2009","unstructured":"Lindgren, P., Geborek, P., Kobelt, G.: Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from southern Sweden. Int. J. Technol. Assess. Health Care 25, 181\u2013189 (2009)","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"685_CR47","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1185\/030079906X132389","volume":"22","author":"S Dewilde","year":"2006","unstructured":"Dewilde, S., Turk, F., Tambour, M., Sandstr\u00f6m, T.: The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr. Med. Res. Opin. 22, 1765\u20131776 (2006)","journal-title":"Curr. Med. Res. Opin."},{"key":"685_CR48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/03009740701607224","volume":"37","author":"G Kobelt","year":"2008","unstructured":"Kobelt, G., Sobocki, P., Mulero, J., Gratacos, J., Collantes-Estevez, E., Braun, J.: The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. Scand. J. Rheumatol. 37, 62\u201371 (2008)","journal-title":"Scand. J. Rheumatol."},{"key":"685_CR49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/ard.2003.010629","volume":"63","author":"G Kobelt","year":"2004","unstructured":"Kobelt, G., Eberhardt, K., Geborek, P.: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. 63, 4\u201310 (2004)","journal-title":"Ann. Rheum. Dis."},{"key":"685_CR50","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/keg107","volume":"42","author":"G Kobelt","year":"2003","unstructured":"Kobelt, G., J\u00f6nsson, L., Young, A., Eberhardt, K.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 42, 326\u2013335 (2003)","journal-title":"Rheumatology (Oxford)"},{"key":"685_CR51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458507086667","volume":"14","author":"G Kobelt","year":"2008","unstructured":"Kobelt, G., Berg, J., Lindgren, P., Jonsson, B., Stawiarz, L., Hillert, J.: Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult. Scler. 14, 679\u2013690 (2008)","journal-title":"Mult. Scler."},{"key":"685_CR52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/02841860601096841","volume":"46","author":"J Norum","year":"2007","unstructured":"Norum, J., Olsen, J.A., Wist, E.A., L\u00f8nning, P.E.: Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 46, 153\u2013164 (2007)","journal-title":"Acta Oncol."},{"key":"685_CR53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/ard.2004.032565","volume":"65","author":"A Boonen","year":"2006","unstructured":"Boonen, A., van der Heijde, D., Severens, J.L., Boendermaker, A., Landew\u00e9, R., Braun, J., Brandt, J., Sieper, J., van der Linden, S.: Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann. Rheum. Dis. 65, 201\u2013208 (2006)","journal-title":"Ann. Rheum. Dis."},{"key":"685_CR54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdm488","volume":"19","author":"M Lidgren","year":"2008","unstructured":"Lidgren, M., J\u00f6nsson, B., Rehnberg, C., Willking, N., Bergh, J.: Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann. Oncol. 19, 487\u2013495 (2008)","journal-title":"Ann. Oncol."},{"key":"685_CR55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","volume":"26","author":"C McCabe","year":"2008","unstructured":"McCabe, C., Claxton, K., Culyer, A.J.: The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26, 733\u2013744 (2008)","journal-title":"Pharmacoeconomics"},{"key":"685_CR56","unstructured":"Raad voor de Volksgezondheid en Zorg: Zinnige en duurzame zorg. http:\/\/www.rvz.net\/data\/download\/advies_Zinnige_zorg.pdf (2006). Accessed 22 June 2013"},{"key":"685_CR57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-6296(96)00507-3","volume":"16","author":"D Meltzer","year":"1997","unstructured":"Meltzer, D.: Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16, 33\u201364 (1997)","journal-title":"J Health Econ"},{"key":"685_CR58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jclinepi.2004.06.016","volume":"58","author":"WJ Meerding","year":"2005","unstructured":"Meerding, W.J., IJzelenberg, W., Koopmanschap, M.A., Severens, J.L., Burdorf, A.: Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J. Clin. Epidemiol. 58, 517\u2013523 (2005)","journal-title":"J. Clin. Epidemiol."},{"key":"685_CR59","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3899\/jrheum.100123","volume":"37","author":"W Zhang","year":"2010","unstructured":"Zhang, W., Gignac, M.A., Beaton, D., Tang, K., Anis, A.H.: Canadian Arthritis Network Work Productivity Group: productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J. Rheumatol. 37, 1805\u20131814 (2010)","journal-title":"J. Rheumatol."},{"key":"685_CR60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200523020-00002","volume":"23","author":"WB Brouwer","year":"2005","unstructured":"Brouwer, W.B., Koopmanschap, M.A.: The friction-cost method : replacement for nothing and leisure for free? Pharmacoeconomics 23, 105\u2013111 (2005)","journal-title":"Pharmacoeconomics"},{"key":"685_CR61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00019053-200523020-00001","volume":"23","author":"H Birnbaum","year":"2005","unstructured":"Birnbaum, H.: Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics 23, 103\u2013104 (2005)","journal-title":"Pharmacoeconomics"},{"key":"685_CR62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<253::AID-HEC266>3.0.CO;2-6","volume":"6","author":"WB Brouwer","year":"1997","unstructured":"Brouwer, W.B., Koopmanschap, M.A., Rutten, F.F.: Productivity costs measurement through quality of life? A response to the recommendation of the Washington panel. Health Econ. 6, 253\u2013259 (1997)","journal-title":"Health Econ."},{"key":"685_CR63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0167-6296(97)00006-4","volume":"16","author":"M Johannesson","year":"1997","unstructured":"Johannesson, M., Karlsson, G.: The friction cost method: a comment. J. Health Econ 16, 249\u2013255 (1997). (discussion 257\u2013259)","journal-title":"J. Health Econ"},{"key":"685_CR64","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hec.1795","volume":"21","author":"J Nyman","year":"2012","unstructured":"Nyman, J.: Productivity costs revisited: toward a new US policy. Health Econ. 21, 1387\u20131401 (2012)","journal-title":"Health Econ."},{"key":"685_CR65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1524-4733.2009.00614.x","volume":"13","author":"C Tilling","year":"2010","unstructured":"Tilling, C., Krol, M., Tsuchiya, A., Brazier, J., Brouwer, W.: In or out? Income losses in health state valuations: a review. Value Health 13, 298\u2013305 (2010)","journal-title":"Value Health"},{"key":"685_CR66","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1524-4733.2010.00699.x","volume":"13","author":"S Knies","year":"2010","unstructured":"Knies, S., Severens, J.L., Ament, A.J., Evers, S.M.: The transferability of valuing lost productivity across jurisdictions. Differences between national pharmacoeconomic guidelines. Value Health 13, 519\u2013527 (2010)","journal-title":"Value Health"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-015-0685-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-015-0685-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-015-0685-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T11:57:11Z","timestamp":1717847831000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-015-0685-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,16]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1007\/s10198-015-0685-x","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,16]]}}}